/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) ("Fusion"), a clinical-stage oncology company focused on developing next-generation targeted alpha.
Fusion Pharmaceuticals (FUSN) Announces 17.6M Share Offering at $3.40/sh, Acquires Phase 2 Program for 225Ac-PSMA I&T streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.